Emily Menendez

GU Oncology Now

Renal medullary carcinoma (RMC) is one of the most aggressive forms of kidney cancer, and traditional treatments are often not very effective, resulting in a need for new strategies. Recent studies have shown the potential therapeutic role of immune checkpoint inhibitors (ICIs) for the treatment of RMC.Researchers from the University of Texas MD Anderson Cancer Center and West Virginia University <a href="https://www.mdpi.com/2072-6694/15/15/3806/htm" target="_blank" rel="noopener">carried out the first evaluation of ICIs in patients with RMC</a> to determine their effectiveness.A small group of 5 patients with locally advanced or metastatic RMC were administered pembrolizumab 200 mg intravenously every 21 days as part of a phase 2 basket trial. Tumor tissues were evaluated for programmed cell death ligand 1 (PD-L1) expression and tumor-infiltrating lymphocyte (TIL) levels. Targeted next-generation sequencing was used to assess somatic mutations.The majority of patients (60%) had metastatic disease at diagnosis, and all patients had advanced disease. Despite treatment with pembrolizumab, each patient experienced rapid disease progression, with a median time to progression of 8.7 weeks. One patient experienced sudden clinical progression immediately after treatment initiation and was pulled from the trial less than 1 week after receiving pembrolizumab.This evaluation of pembrolizumab for the treatment of RMC showed no evidence of clinical activity, irrespective of PD-L1 or TIL levels.

Pembrolizumab Shows No Benefit in Patients With RMC

nccRCC

As one of the most aggressive forms of kidney cancer, there is a need for new treatment strategies for renal medullary carcinoma.

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe